Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MDM2 amp |
Therapy | GDC-0575 + Gemcitabine |
Indication/Tumor Type | liposarcoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 amp | liposarcoma | predicted - sensitive | GDC-0575 + Gemcitabine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, GDC-0575 and Gemzar (gemcitabine) synergistically induced apoptosis and cell cycle arrest in liposarcoma cells harboring MDM2 amplification in culture, and inhibited tumor growth, prolonged progression-free survival in cell line xenogrft models (PMID: 29409053). | 29409053 |
PubMed Id | Reference Title | Details |
---|---|---|
(29409053) | CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications. | Full reference... |